Oculis Holding AG
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Oculis Holding AG now
Current reporting with the operating signal separated from the noise.
OCSAW Oculis Holding AG WT EXP 030628
The story matters when it changes Oculis Holding AG’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Oculis Holding AG: Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
The story matters when it changes Oculis Holding AG’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Oculis Holding AG (OCS) Securities Fraud Investigation
The story matters when it changes Oculis Holding AG’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud
The story matters when it changes Oculis Holding AG’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Oculis Holding AG (OCS) Reports Q1 Loss, Lags Revenue Estimates
Investors are testing whether Oculis Holding AG’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Oculis Holding AG: Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses
The story matters when it changes Oculis Holding AG’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Oculis Holding AG Reports Q2 2025 Financial Progress
The story matters when it changes Oculis Holding AG’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Oculis Holding AG Reports Positive Phase 2 ACUITY Trial Results for OCS-05 as Potential Therapy for Acute Optic Neuritis
The story matters when it changes Oculis Holding AG’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.Latest OCS filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Oculis Holding AG, quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
SEARCH Q2 COVERAGE →Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →Fourth quarter / full year
No verified period-specific item in the current feed.
SEARCH Q4 COVERAGE →